FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
This article was originally published in The Tan Sheet
Executive Summary
FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B
You may also be interested in...
Barr, FDA Will Meet On Plan B Switch; Agency Says Rulemaking Not Needed
The approval process for the over-the-counter sale of Barr's emergency contraceptive Plan B could be "wrapped up in a matter of weeks if [Barr and FDA] work diligently" together, according to an FDA spokesperson
Barr, FDA Will Meet On Plan B Switch; Agency Says Rulemaking Not Needed
The approval process for the over-the-counter sale of Barr's emergency contraceptive Plan B could be "wrapped up in a matter of weeks if [Barr and FDA] work diligently" together, according to an FDA spokesperson
Barr, FDA Will Meet On Plan B Switch; Agency Says Rulemaking Not Needed
The approval process for the over-the-counter sale of Barr's emergency contraceptive Plan B could be "wrapped up in a matter of weeks if [Barr and FDA] work diligently" together, according to an FDA spokesperson